Buy Fortis Healthcare; target of Rs 360: Prabhudas Lilladher
Prabhudas Lilladher is bullish on Fortis Healthcare has recommended buy rating on the stock with a target price of Rs 360 in its research report dated February 13, 2023.15-02-2023
15-02-2023
FORTIS HEALTHCARE LTD. - 532843 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of the investors / analysts meet held on February 13, 2023 to discuss the Company's un-audited financial results for the quarter ended December 31, 2022 is available on the website of the Company i.e. https://www.fortishealthcare.com/investors.14-02-2023
FORTIS HEALTHCARE LTD. - 532843 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copies of newspaper advertisements published on February 11, 2023 in the columns of English daily 'Financial Express', all editions and Punjabi daily 'Rozana Spokesman', Mohali edition, with respect to un-audited financial results of the Company for the quarter and period ended on December 31, 2022.11-02-2023
Fortis Healthcare reports flat December quarter profit at Rs 142 crore
Fortis Healthcare on Friday reported a flat December quarter net profit at Rs 142 crore. The healthcare provider had posted a net profit of Rs 142 crore in the October-December quarter of the last fiscal. Revenue from operations rose to Rs 1,560 crore in the third quarter as compared to Rs 1,467 crore in the year-ago period, Fortis Healthcare said in a regulatory filing. "Our hospital business is growing from strength to strength and today contributes to more than 75 per cent of our overall earnings (EBITDA). "It is also pertinent to highlight that the hospital performance has by and large offset the decline we have seen in the diagnostics business primarily as a result of the decline in Covid volumes," Fortis Healthcare Chairman Ravi Rajagopal noted. Revenues from key medical specialties are gaining traction, complimented by focus on continuing to onboard quality medical talent and investments in bed expansion in facilities such as Mulund and BG Road and in medical equipment such10-02-2023
FORTIS HEALTHCARE LTD. - 532843 - Outcome Of The Board Meeting And Disclosure Under Regulation 30 Of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015
Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e. February 10, 2023, inter-alia, considered and approved the Standalone and Consolidated un-audited financial results of the Company for the quarter and period ended on December 31, 2022. Accordingly, please find enclosed standalone and consolidated un-audited financial results along with limited review report given by the Statutory Auditor of the Company for the quarter and period ended on December 31, 2022. Further, a copy of the press release and investor presentation being issued in this regard is also enclosed.10-02-2023
FORTIS HEALTHCARE LTD. - 532843 - Board Meeting Outcome for Outcome Of The Board Meeting And Disclosure Under Regulation 30 Of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015
Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e. February 10, 2023, inter-alia, considered and approved the Standalone and Consolidated un-audited financial results of the Company for the quarter and period ended on December 31, 2022. Accordingly, please find enclosed standalone and consolidated un-audited financial results along with limited review report given by the Statutory Auditor of the Company for the quarter and period ended on December 31, 2022. Further, a copy of the press release and investor presentation being issued in this regard is also enclosed. The meeting commenced at 1100 Hours IST and concluded at 1930 Hours IST10-02-2023
FORTIS HEALTHCARE LTD. - 532843 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
In compliance of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find below schedule of upcoming conference call invite to discuss the Company's un-audited financial results for the quarter ended December 31, 2022: Date & Time: February 13, 2023 at 11:00 A.M. (IST) Investors / Analysts / Events: Q3FY23 Post Results Conference Call Invite. Location: Virtual Conference. Please find enclosed herewith dial-in numbers alongwith participation link. No Unpublished Price Sensitive Information (UPSI) shall be shared / discussed at the investors / analysts' meet.08-02-2023
FORTIS HEALTHCARE LTD. - 532843 - Board Meeting Intimation for Notice Of Board Meeting Under Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
FORTIS HEALTHCARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2023 ,inter alia, to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, notice is hereby given that a meeting of the Board of Directors of the Company will be held on Friday, February 10, 2023 to, inter-alia, consider and approve un-audited financial results for the quarter ended December 31, 2022. Further, in continuation to our letter ref. FHL/SEC/2022-23 dated December 29, 2022 captioned 'Closure of Trading Window', it is hereby informed that the trading window of the Company for dealing in securities of the Company will remain closed till February 12, 2023.03-02-2023
FORTIS HEALTHCARE LTD. - 532843 - Announcement under Regulation 30 (LODR)-Credit Rating
In compliance of Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, please note that CRISIL Ratings Limited has revised rating of the Company and its subsidiaries, as detailed in the enclosed letter. The detailed letters as issued by CRISIL Ratings Limited to the Company and subsidiaries are enclosed for your reference and records.02-02-2023
Fortis in Bengaluru completes 500 robotic aided urology procedures
The 500 robot-aided surgeries include complex robotic procedures encompassing the entire gamut of Uro-Oncology, Uro-Gynaecology, Reconstructive Urology and Kidney Transplant16-01-2023